索磷布韦首剂给药后在一名接受普萘洛尔而非胺碘酮治疗的患者中出现室性期前收缩：一例报告
Ventricular Extrasystoles after First Dose of Sofosbuvir in a Patient Treated with Propranolol but not with Amiodarone: A Case Report.
作者信息
Rouabhia Samir, Baghazza Sabah, Sadouki Hamza, Djezzar Sihem, Bencherif Rafik, Guehimeche Rofia, Sadelaoud Mourad, Mallem Djamel, Chaabna Karima
机构信息
Department of Internal Medicine, University Hospital Center Touhami Benflis, Batna 05000, Algeria and Department of Medicine, University Batna 2, Batna 05000. Algeria.
Department of Internal Medicine, University Hospital Center Touhami Benflis, Batna 05000. Algeria.
出版信息
Rev Recent Clin Trials. 2017;12(3):159-161. doi: 10.2174/1574887112666170725132044.
BACKGROUND
Sofosbuvir is a direct-acting antiviral drug used to treat chronic hepatitis C infection. In 2015, Gilead Sciences, the manufacturer of sofosbuvir, warned that bradycardia could occur when sofosbuvir is administered in combination with amiodarone. Interestingly, among the reported cases of patients with sofosbuvir and amiodarone related bradycardia, some of them were also treated with propranolol.
OBJECTIVE
We herein report a case of ventricular extrasystoles within three hours after the coadministration of sofosbuvir-containing regimen with propranolol. This patient had never been treated with amiodarone. After the sofosbuvir-containing regimen was stopped, ventricular extrasystoles disappeared within 24 hours. This observation suggests that the association of sofosbuvir with propranolol may have a role in the emergence of cardiac arrhythmia.
CONCLUSION
Patients treated with amiodarone and/or propranolol should be continuously monitored within the early hours following the initiation of sofosbuvir.
背景
索磷布韦是一种用于治疗慢性丙型肝炎感染的直接作用抗病毒药物。2015年，索磷布韦的制造商吉利德科学公司警告称，索磷布韦与胺碘酮联合使用时可能会发生心动过缓。有趣的是，在报告的索磷布韦与胺碘酮相关心动过缓患者病例中，其中一些患者还接受了普萘洛尔治疗。
目的
我们在此报告一例在含索磷布韦方案与普萘洛尔联合用药后三小时内出现室性期前收缩的病例。该患者从未接受过胺碘酮治疗。停用含索磷布韦方案后，室性期前收缩在24小时内消失。这一观察结果表明，索磷布韦与普萘洛尔的联合使用可能在心律失常的发生中起作用。
结论
在开始使用索磷布韦后的早期数小时内，应持续监测接受胺碘酮和/或普萘洛尔治疗的患者。
Zotero 插件